Innovent Reports the NMPA Approval of Sycume for Thyroid Eye Disease
Shots:
- China’s NMPA has approved Sycume for the treatment of thyroid eye disease (TED)
- Approval was based on P-III (RESTORE-1) trial in TED pts, which met its 1EP in 2024, with 85.8% pts achieving ≥2mm proptosis reduction at 24wks., along with improved inflammation & QoL; data was presented at WOC, CSE, and CCOS
- Sycume (teprotumumab N01) blocks IGF-1R signalling to reduce inflammatory factor expression & hyaluronic acid synthesis, along with other glycosaminoglycans synthesis from OFs activation. It also prevents OF differentiation into adipocytes/myofibroblasts to lower disease activity & improve symptoms such as proptosis, diplopia, orbital congestion, & edema
Ref: Prnewswire | Image: Innovent
Related News:- Innovent Reports the NMPA’s NDA Acceptance & Priority Review of Neoadjuvant Ipilimumab + Sintilimab for Colon Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
